SymbolEQ
NameEQUILLIUM, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address2223 AVENIDA DE LA PLAYA,SUITE 105, LA JOLLA, California, 92037, United States
Telephone+1 858 240-1200
Fax
Email
Websitehttps://www.equilliumbio.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001746466
Description

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Additional info from NASDAQ:
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

2026-06-05 21:07

📋 Connelly Stephen (Officer) plans to sell 31K shares of Equillium, Inc. (at $2.94 each, total $91K) Filed: Jun 05, 2026 | ID: 000073

Read more
2026-06-05 20:42

Zedelmayer Christine 🟡 adjusted position in 14.6K shares (1 derivative) of Equillium, Inc. (EQ) at $2.93 Transaction Date: Jun 05, 2026 | Filing ID: 000011

Read more
2026-06-05 20:42

Connelly Stephen 🔴 sold 231.0K shares of Equillium, Inc. (EQ) at $3.16 Transaction Date: Jun 04, 2026 | Filing ID: 000004

Read more
2026-06-04 21:30

📋 Connelly Stephen (Officer) plans to sell 200K shares of Equillium, Inc (at $3.16 each, total $633K) Filed: Jun 04, 2026 | ID: 000071

Read more
2026-06-02 20:05

Equillium - Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-06-02 20:05

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-05-29 22:28

Tom Penny 🟡 adjusted position in 65.0K shares (1 derivative) of Equillium, Inc. (EQ) at $2.95 Transaction Date: May 28, 2026 | Filing ID: 000002

Read more
2026-05-29 22:27

DEMSKI MARTHA J 🟢 acquired 70.0K shares (1 derivative) of Equillium, Inc. (EQ) at $2.84 Transaction Date: May 28, 2026 | Filing ID: 000003

Read more
2026-05-29 22:25

Pruzanski Mark 🟢 acquired 70.0K shares (1 derivative) of Equillium, Inc. (EQ) at $2.84 Transaction Date: May 28, 2026 | Filing ID: 000001

Read more
2026-05-29 22:23

BRADBURY DANIEL 🟢 acquired 70.0K shares (1 derivative) of Equillium, Inc. (EQ) at $2.84 Transaction Date: May 28, 2026 | Filing ID: 000003

Read more